I. Disposition of a Farnesylethyl α-Phosphonosulfonate and Ester Prodrugs in Rats
Abstract
The disposition of I [(E,E)-6,10,14-trimethyl-1-phosphono-5,9,13-pentadecatriene-1-sulfonic acid] and its mono- (II), di- (III), and triester (IV) prodrugs in rats was studied with14C-labeled compounds. After iv administration of I (15 μmol/kg), radioactivity in plasma was measurable up to 96 hr and averaged 0.026 μg-eq/ml. I accounted for >50% of the radioactivity in plasma and had an apparent half-life of 4 hr. After oral administration of the same dose, the maximal plasma concentration of radioactivity averaged 0.108 μg-eq/ml at 6 hr. In 96 hr, 19 and 73% of the iv dose and 2 and 97% of the po dose was excreted in urine and feces, respectively. The absorption was 2.4%, based on the plasma data. In 12 hr after an iv dose of I to bile duct-cannulated rats, 41 and 14% of the dose was excreted in bile and urine, respectively. I accounted for 51% of the radioactivity in bile and a negligible amount in urine. At 12 hr after iv dosing, liver retained 31% of the dose. No accumulation of radioactivity in bone was observed. I (3%) and II (6%) were poorly absorbed. Enhanced absorption was observed for III (80%) and IV (45%). No I or metabolites of I were found in bile or urine of rats dosed with the prodrugs. The structures of two metabolites each for I, III, and IV were proposed. Together, they accounted for >80% of the radioactivity in urine and ∼50% of the radioactivity in bile for each compound. Metabolism appeared to occur primarily at the farnesyl moiety, presumably by the same pathways as for farnesyl-1-pyrophosphate.
Footnotes
-
Send reprint requests to: Shih-Jung Lan, Ph.D., Metabolism and Pharmacokinetics Department, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, NJ 08543.
- Abbreviations used are::
- FPP
- farnesyl-1-pyrophosphate
- BDC
- bile duct-cannulated
- TBAS
- tetrabutyl ammonium hydrogen sulfate
- Received December 5, 1997.
- Accepted June 4, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|